120.56USD-1.52%Mkt Cap: 297.89B USDP/E: 33.97Last update: 2026-05-26
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxi…
Industry Peers
Drug Manufacturers - GeneralIndicators:|
Key Statistics
Company
Market Cap297.89B USD
Enterprise Value329.67B USD
Revenue (TTM)65.77B USD
Gross Profit48.63B USD
Net Income (TTM)18.25B USD
Revenue/Share26.42 USD
Last Price120.56 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees73.0K
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - General
ISINUS58933Y1055
Valuation
P/E (Trailing)33.97
P/E (Forward)12.17
PEG5.25
EV/EBITDA11.17
EV/Revenue5.01
P/S4.35
P/B6.24
EPS (TTM)3.55
EPS (Forward)9.52
52W Range
75.4091% of range125.14
52W High125.14 USD
52W Low75.40 USD
Profitability
Gross Margin74.80%
Oper. Margin38.60%
EBITDA Margin44.88%
Profit Margin28.08%
ROE34.70%
ROA13.34%
Growth
Revenue Growth4.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF16.47B USD
CapEx (TTM)4.11B USD
FCF Margin21.36%
FCF Yield4.72%
Net Debt43.41B USD
Net Debt/EBITDA1.47
Balance Sheet
Debt/Equity0.94
Current Ratio1.30
Quick Ratio0.70
Book Value/Sh18.58 USD
Cash/Share2.309 USD
Dividends
Fwd Div Rate3.400 USD
Trail. Div Rate3.280 USD
Div. Yield2.93%
5Y Avg Yield3.02%
Payout Ratio93.52%
Ex-Div DateMar 16, 2026
Pay DateApr 7, 2026
Splits
Last Split1048:1000
Split DateJun 3, 2021
Analyst Consensus
Rating1.8 (Buy)
Target (Mean)129.74 USD
Target Range100.00 USD – 150.00 USD
# Analysts27
Ownership
Shares Out.2.47B
Float2.47B
Insiders0.06%
Institutions82.17%
Short Interest
Short Ratio2.8d
Short % Float1.06%
Short % Out.1.06%
Shares Short26.21M
Short (prev mo.)27.72M
Technical
SMA 50115.57 (+4.3%)
SMA 200102.09 (+18.1%)
Beta0.20
S&P 52W Chg28.31%
Avg Vol (30d)9.10M
Avg Vol (10d)7.81M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—